The impact of the AIDS Drug Assistance Program (ADAP) on use of highly active antiretroviral and antihypertensive therapy among HIV-infected women.
OBJECTIVE
To evaluate the association between enrollment into an AIDS Drug Assistance Program (ADAP) and use of highly active antiretroviral therapy (HAART) and antihypertensive therapy.


METHODS
Cross-sectional analyses of data were performed on HAART-eligible women enrolled in the California (n = 439), Illinois (n = 168), and New York (n = 487) Women's Interagency HIV Study sites. A subset of HIV-infected women with hypertension (n = 395) was also analyzed. Unadjusted and adjusted backward stepwise elimination logistic regression measured the association between demographic, behavioral, and health service factors and nonuse of HAART or antihypertensive medication.


RESULTS
In adjusted analysis of HAART nonuse, women without ADAP were significantly more likely not to use HAART (odds ratio [OR], 2.4; 95% confidence interval [CI], 1.5-3.7) than women with ADAP. In adjusted analysis of antihypertensive medication nonuse, women without ADAP had an increased but not significant odds of antihypertensive medication nonuse (OR, 2.4; 95% CI, 0.93-6.0) than women with ADAP.


CONCLUSIONS
Government-funded programs for prescription drug coverage such as ADAP may play an important role in how HIV-positive women access and use essential medications for chronic diseases.
School of Pharmacy, University of California, San Francisco, CA 94122, USA.
Thomas
T
Yi
Jennifer
J
Cocohoba
Mardge
M
Cohen
Kathryn
K
Anastos
Jack A
JA
DeHovitz
Naoko
N
Kono
David B
DB
Hanna
Nancy A
NA
Hessol
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D002140:California; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007087:Illinois; D008875:Middle Aged; D009518:New York; D016903:Drug Monitoring
D019380:Anti-HIV Agents; D000959:Antihypertensive Agents
Med Clin North Am. 2005 Jul;89(4):895-912
15925655
Clin Diagn Lab Immunol. 2005 Sep;12(9):1013-9
16148165
J Epidemiol Community Health. 2008 Sep;62(9):798-803
18701730
J Clin Hypertens (Greenwich). 2007 May;9(5):345-54
17485970
Am J Public Health. 2002 Jan;92(1):82-7
11772767
Am J Public Health. 2010 Aug;100(8):1493-9
19910347
Am J Public Health. 2002 May;92(5):852-7
11988459
J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Mar 1;8(3):253-65
7859137
Cardiol Rev. 2006 Nov-Dec;14(6):267-75
17053372
Circulation. 1997 Nov 4;96(9):3243-7
9386200
Arch Intern Med. 2005 Oct 10;165(18):2098-104
16216999
MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19
1361652
Am J Hypertens. 2008 Jul;21(7):789-98
18451806
Epidemiology. 1998 Mar;9(2):117-25
9504278
J Acquir Immune Defic Syndr. 2000 Oct 1;25(2):115-23
11103041
Am J Public Health. 2004 Jul;94(7):1147-51
15226135
BMC Public Health. 2006 Mar 14;6:66
16536868
Nephrol Dial Transplant. 2004 Sep;19(9):2250-8
15238630
J Hypertens. 2003 Jul;21(7):1377-82
12817187
Health Serv Res. 2000 Jun;35(2):389-416
10857469
J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):96-103
15608532
JAMA. 2009 Feb 25;301(8):848-57
19244192